Details of the Drug Combination

General Information of Drug Combination (ID: DCFPU58)

Drug Combination Name
Levamisole Eptifibatide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Levamisole   DM5EN79 Eptifibatide   DMQXTJS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 66.62
Bliss Independence Score: 66.62
Loewe Additivity Score: 81.02
LHighest Single Agent (HSA) Score: 81.04

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Levamisole
Disease Entry ICD 11 Status REF
Parasitic infection 1D0Y-1G2Z Approved [2]
Colon cancer 2B90.Z Withdrawn from market [3]
Levamisole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Alkaline phosphatase tissue-nonspecific (ALPL) TTMR5UV PPBT_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Levamisole Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [7]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Eptifibatide
Disease Entry ICD 11 Status REF
Acute cardiac ischemic events BA40.Z Approved [4]
Acute coronary syndrome BA41 Approved [5]
Pneumonia CA40 Approved [5]
Eptifibatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [8]
------------------------------------------------------------------------------------
Eptifibatide Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Prothrombin (F2) OTNFSM49 THRB_HUMAN Increases Expression [9]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Increases Expression [9]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [9]
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases ADR [10]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7210).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6585).
5 Eptifibatide FDA Label
6 Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.
7 Levamisole induced apoptosis in cultured vascular endothelial cells. Br J Pharmacol. 2000 Dec;131(8):1577-83.
8 Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
9 Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.